The chemopreventive efficacies of nonsteroidal anti-inflammatory drugs: The relationship of short-term biomarkers to long-term skin tumor outcome

Cancer Prevention Research

Volumn 6, Issue 7, 2013, Pages 675-685

  Mikulec, Carol D ^a   Rundhaug, Joyce E ^a   Simper, Melissa S ^a   Lubet, Ronald A ^b   Fischer, Susan M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROOXYMETHYLPHENYLASPIRIN; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; BIOLOGICAL MARKER; CELECOXIB; CYCLOOXYGENASE 2; INDOMETACIN; NAPROXEN; PROSTAGLANDIN E2; SULINDAC; UNCLASSIFIED DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; EPIDERMIS; FEMALE; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; SKIN TUMOR; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECTS; HAIRLESS MOUSE; HUMAN; METABOLISM; PATHOLOGY; RADIATION RESPONSE; SKIN NEOPLASMS; ULTRAVIOLET RADIATION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; ASPIRIN; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; DINOPROSTONE; FEMALE; HUMANS; KERATINOCYTES; MICE; MICE, HAIRLESS; NAPROXEN; SKIN NEOPLASMS; SULINDAC; TUMOR MARKERS, BIOLOGICAL; ULTRAVIOLET RAYS;

EID: 84880049063     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0064     Document Type: Article

References (40)

1. Ananthaswamy HN. Ultraviolet light as a carcinogen. In: Bowden GT, Fischer SM, editors. Chemical carcinogens and anticarcinogens. Cambridge, UK: Cambridge University Press; 1997. p. 255-79.
2. Dlugosz AA, Yuspa SH. Staurosporine induces protein kinase C agonist effects and maturation of normal and neoplastic mouse keratinocytes in vitro. Cancer Res 1991;51:4677-84.
3. Hruza LL, Pentland AP. Mechanisms of UV-induced inflammation. J Invest Dermatol 1993;100:35S-41S.
4. Muller-Decker K. Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence. Cancer Metastasis Rev 2011;30:343-61.
5. Rundhaug JE, Fischer SM. Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis. Photochem Photobiol 2008;84: 322-9.
6. Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999;25:231-40.
7. Fischer SM, Hawk ET, Lubet RA. Coxibs and other nonsteroidal antiinflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res 2011;4:1728-35.
8. Lanas A, Perez-Aisa MA, Feu F, Ponce J, Saperas E, Santolaria S, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use.AmJ Gastroenterol 2005;100: 1685-93.
9. Rigas B, Williams JL. NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide 2008;19:199-204.
10. Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Drozdowicz D, Kwiecien S, et al. Gastroprotective and ulcer healing effects of nitric oxide-releasing non-steroidal anti-inflammatory drugs. Dig Liver Dis 2000;32:583-94.
11. Steele VE, Rao CV, Zhang Y, Patlolla J, Boring D, Kopelovich L, et al. Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers. Cancer Prev Res 2009;2:951-6.
12. Fischer SM, Pavone A, Mikulec C, Langenbach R, Rundhaug JE. Cyclooxygenase-2 expression is critical for chronic UV-induced murine skin carcinogenesis. Mol Carcinog 2007;46:363-71.
13. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-32.
14. Ono R, Masaki T, Dien S, Yu X, Fukunaga A, Yodoi J, et al. Suppressive effect of recombinant human thioredoxin on ultraviolet light-induced inflammation and apoptosis in murine skin. J Dermatol 2012;39:843-51.
15. Maldve RE, Kim Y, Muga SJ, Fischer SM. Prostaglandin E(2) regulation of cyclooxygenase expression in keratinocytes is mediated via cyclic nucleotide-linked prostaglandin receptors. J LipidRes 2000;41:873-81.
16. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012;166:1069-80.
17. Firnhaber JM. Diagnosis and treatment of Basal cell and squamous cell carcinoma. Am Fam Physician 2012;86:161-8.
18. Rundhaug JE, Mikulec C, Pavone A, Fischer SM. A role for cyclooxygenase- 2 in ultraviolet light-induced skin carcinogenesis. Mol Carcinog 2007;46:692-8.
19. Duggan KC, Walters MJ, Musee J, Harp JM, Kiefer JR, Oates JA, et al. Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. J Biol Chem 2010;285:34950-9.
20. Fosbol EL, Kober L, Torp-Pedersen C, Gislason GH. Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals. Expert Opin Drug Saf 2010;9:893-903.
21. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 2007;82:85-94.
22. Curiel-Lewandrowski C, Swetter SM, Einspahr JG, Hsu CH, Nagle R, Sagerman P, et al. Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity. Cancer 2012;118:5848-56.
23. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo- controlled, double-blind trial. Cancer Prev Res 2008;1:32-8.
24. Takeuchi K, Suzuki K, Yamamoto H, Araki H, Mizoguchi H, Ukawa H. Cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs and gastric mucosal responses. J Physiol Pharmacol 1998;49:501-13.
25. Abel EL, Angel JM, Kiguchi K, DiGiovanni J. Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat Protoc 2009;4:1350-62.
26. Marks F, FurstenbergerG, Muller-Decker K. Tumor promotion as a target of cancer prevention. Recent Results Cancer Res 2007;174:37-47.
27. Ansari KM, Rundhaug JE, Fischer SM. Multiple signaling pathways are responsible for prostaglandin E2-induced murine keratinocyte proliferation. Mol Cancer Res 2008;6:1003-16.
28. Miyoshi J, Yajima T, Shimamura K, Matsuoka K, Okamoto S, Higuchi H, et al. 5-aminosalicylic acid mediates expression of cyclooxygenase- 2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis. Anticancer Res 2012;32:1193-202.
29. Athar M, An KP, Tang X, Morel KD, Kim AL, Kopelovich L, et al. Photoprotective effects of sulindac against ultraviolet B-induced phototoxicity in the skin of SKH-1 hairless mice. Toxicol Appl Pharmacol 2004;195:370-8.
30. Kim DJ, Prabhu KS, Gonzalez FJ, Peters JM. Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Carcinogenesis 2006;27:1105-12.
31. Cheng KW, Mattheolabakis G, Wong CC, Ouyang N, Huang L, Constantinides PP, et al. Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer. Int J Oncol 2012.
32. Gonzalez Maglio DH, Paz ML, Ferrari A, Weill FS, Nieto J, Leoni J. Alterations in skin immune response throughout chronic UVB irradiation- skin cancer development and prevention by naproxen. Photochem Photobiol 2010;86:146-52.
33. BairWBIII, Hart N, Einspahr J, Liu G, Dong Z, Alberts D, et al. Inhibitory effects of sodium salicylate and acetylsalicylic acid on UVB-induced mouse skin carcinogenesis. Cancer Epidemiol Biomarkers Prev 2002;11:1645-52.
34. Huang C, Ma WY, Hanenberger D, Cleary MP, Bowden GT, Dong Z. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J Biol Chem 1997;272: 26325-31.
35. Ouyang N, Williams JL, Tsioulias GJ, Gao J, Iatropoulos MJ, Kopelovich L, et al. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Res 2006;66:4503-11.
36. Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, et al. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 2006;5:1530-8.
37. Jeter JM, Han J, Martinez ME, Alberts DS, Qureshi AA, Feskanich D. Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study. Cancer Causes Control 2012;23:1451-61.
38. Johannesdottir SA, Chang ET, Mehnert F, Schmidt M, Olesen AB, SorensenHT. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer 2012;118: 4768-76.
39. Torti DC, Christensen BC, Storm CA, Fortuny J, Perry AE, Zens MS, et al. Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study. J Am Acad Dermatol 2011;65:304-12.
40. Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2010;102:1835-44.